ArticleFrontiers in immunology2025
Analyzing Hedgehog pathway-related genes: insights into breast cancer tumor microenvironment and prognostic implications.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Study objectives: Given the significant global burden of breast cancer, this study aims to systematically explore the role of Hedgehog (Hh) pathway-related genes in breast cancer prognosis and immunological characteristics. Additionally, we will construct a risk scoring system based on this pathway, with the objective of providing new references for prognostic assessment and immunotherapy strategies. Methods: Key Hh-related genes were identified, and Hedgehog scores were calculated for each sample using the ssGSEA algorithm. These scores were integrated with clinical data. Patients were classified into high-risk and low-risk groups, which were analyzed regarding immune factors, metabolic characteristics, gene mutations, and clinical outcomes. Results: Significant associations were found between the high-risk group and drug sensitivity, immune scores, and overall survival. The findings suggest that immunotherapy may serve as a valuable prognostic tool in breast cancer treatment. Conclusions: This study presents a reliable prognostic system based on the Hh pathway score for breast cancer prognosis and drug responsiveness. The results underscore the potential of immunotherapy in improving prognosis and emphasize the need for further clinical validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.